Our foundational and robust science supports future expansion opportunities into other indications, which could include hepatic, renal, and cardiac fibrosis. Our Pipeline Target Clinical Candidate …

Our Pipeline About Us News & Events Careers Contact Privacy Policy Accessibility Statement

“With the formation of our CAB, we bring together a wealth of experience and expertise to help advance the clinical development of our pipeline as we work to address the significant unmet need in fibrosis,” …

Jun 5, 2025 · Mediar Therapeutics Doses First Patient in Phase 2 WISPer Trial of MTX-463 for Idiopathic Pulmonary Fibrosis June 5, 2025 Mediar Therapeutics, Inc., a clinical-stage biotechnology …

Jan 15, 2025 · Eli Lilly is making a play for the idiopathic pulmonary fibrosis (IPF) market, offering Mediar Therapeutics $99 million in upfront and near-term payments for global rights to an asset that is …

Expanded Access Policy for MTX-463 Expanded access, also called compassionate use, refers to the use of an investigational therapy outside of a clinical trial designed to evaluate safety and efficacy. …

© 2025 Mediar Therapeutics Website design/development: Graphic Beans Our Pipeline About Us News & Events Careers Contact Privacy Policy Accessibility Statement

Mediar to advance MTX-463 through an IPF Phase 2 trial, with expected initiation in 1H 2025 BOSTON, Mass., (January 10, 2025) – Mediar Therapeutics, Inc., a clinical stage biotechnology company …

Anti-WISP1 (MTX-463) as a Novel Potential Therapy for Idiopathic Pulmonary Fibrosis Gabriela Dower1, Benjamin T. Wilks1, Christopher Espelin1, Saroj Nepal1, Daniel Tavares1, Chelsea Duncan1, …

MGB-backed biotech raises $85m to develop drugs for diseases that cause scarring in organs